When Is Mohs Surgery the Right Choice? How the Appropriate Use Criteria Were Built

Mohs micrographic surgery is the right choice when a skin cancer combines a high-risk location, aggressive or poorly defined behavior, or a patient whose immune system cannot tolerate a recurrence. That one-sentence rule sounds simple, but the tumor on any given face rarely matches a textbook case. In 2012 a specialist panel published in the Journal of the American Academy of Dermatology set out to make the judgment reproducible. It scored 270 specific tumor-and-patient combinations and rated Mohs appropriate for 200, uncertain for 24, and inappropriate for 46. The result is not a rulebook that decides your case for you. It is a map of where a slower, more expensive technique reliably earns what it costs.

Key points#

• Mohs removes skin cancer in stages and checks nearly the whole surgical margin under the microscope before closing.
• Reported cure rates for previously untreated basal cell carcinoma approach 99 percent in long-term follow-up.
• The 2012 appropriate use criteria (AUC) rated 270 scenarios: 200 appropriate, 24 uncertain, 46 inappropriate.
• Location, tumor behavior, and patient risk are the three levers that move a scenario toward "appropriate."
• "Appropriate" means the expected benefit outweighs the downsides for that indication. It does not mean mandatory.

The problem a rating system had to solve#

For years, whether a patient received Mohs depended heavily on which clinic they walked into. Use of the technique grew quickly, and with that growth came two opposite worries: performing an elaborate procedure on a small, low-stakes lesion, and reaching for a simpler method where a thorough margin check would have prevented a recurrence. Insurers wanted a defensible line between the two. Patients wanted to understand why one cancer warranted a multi-hour staged operation and another did not.

The raw material for an answer already existed. Decades of cure-rate and recurrence data had accumulated. What was missing was a bridge from that evidence to the messy, layered situations that clinical trials never isolate cleanly, for example a moderately aggressive squamous cell carcinoma on the cheek of an organ-transplant recipient. The AUC were designed to be that bridge, pairing published data with structured expert judgment for the combinations real patients actually present.

What sets Mohs apart from a standard excision#

To see why location and behavior matter so much, it helps to understand what the technique buys. A conventional excision removes the visible tumor plus a margin, and the pathology lab later samples slices of that margin, checking a fraction of the true edge. Mohs instead removes tissue in thin layers and examines essentially the entire deep and peripheral margin under the microscope during the same visit. If cancer remains at one edge, the surgeon maps exactly where and takes another layer only there.

Two consequences follow. First, cure rates for previously untreated basal cell carcinoma are commonly reported near 99 percent in long-term follow-up, among the highest for any treatment of these tumors. Second, healthy tissue nearby can be preserved rather than sacrificed to a wider, blind margin. That tissue sparing is decisive on an eyelid, a nasal tip, or a lip, where every millimeter of skin counts.

The cost is real. Mohs takes longer, uses more resources, and asks more of both surgeon and histology lab than a simple excision or a destructive method such as electrodesiccation and curettage. On a small tumor on the back, that extra precision may add little. On a poorly bordered cancer beside the eye, it can be the difference between one clean operation and a disfiguring repeat. The value of the technique is not fixed; it tracks the tumor and the patient, which is precisely what a rating system needed to capture.

How 17 raters turned evidence into a map#

The method behind the AUC did not originate in dermatology. It is the RAND/UCLA Appropriateness Method, a validated modified-Delphi process borrowed from cardiology and radiology, fields that wrestled first with the same appropriateness question. Its purpose is to reveal where evidence and seasoned judgment agree, and just as usefully, where they part ways.

A panel of 17 raters did the scoring: 8 surgeons who perform Mohs and 9 dermatologists who do not, deliberately drawn from varied regions and practice settings so no single perspective could dominate. Each rater scored every scenario on a 9-point scale, where 7 to 9 signaled appropriate, 4 to 6 uncertain, and 1 to 3 inappropriate. They first scored on their own, then met in person and by conference call to work through the scenarios where they disagreed, then rescored across successive rounds. By the end, the group had reached consensus on all 270 scenarios, splitting them into 200 appropriate (74 percent), 24 uncertain (9 percent), and 46 inappropriate (17 percent).

The three levers that move a scenario#

The 270 scenarios are not an arbitrary list. They come from crossing the variables that genuinely shift the risk calculation. The panel worked across four tumor families, basal cell carcinoma, squamous cell carcinoma, lentigo maligna and melanoma in situ, and a group of rarer skin cancers, then combined each with the factors below.

Where the cancer sits#

The body is split into three zones. Area H is the highest-risk group: the central face and other mask-like regions, along with the genitalia, hands, feet, nail units, ankles, and the nipple and areola, all sites where spare tissue is scarce and a recurrence is costly. Area M covers the cheeks, forehead, scalp, neck, jawline, and shins. Area L is the lower-risk trunk and limbs, where a routine excision usually closes without trouble.

How the tumor behaves#

Size, microscopic subtype, and whether a cancer is new or has come back after prior treatment all move the rating. So does aggressive behavior, such as an infiltrative or morpheaform growth pattern, or spread along a nerve. A recurrent tumor with indistinct borders is far harder to clear on the first attempt, which nudges it toward appropriate.

Who the patient is#

The same tumor can warrant different care in different people. Immunosuppression, genetic syndromes that drive many skin cancers, and a history of prior radiation to the site all raise the stakes, because the price of leaving any cancer behind climbs. These factors can push an otherwise borderline scenario into the appropriate column.

Reading the verdict: what "appropriate" actually means#

The word carries a precise definition here. Raters were asked to mark a treatment appropriate when its expected clinical benefit, weighed with clinical judgment, exceeds its likely downsides for a specific indication. That is a comparison, not an order. "Appropriate" is also not the same as "necessary," a line the underlying method draws on purpose. And the criteria stay silent on which alternative is best when Mohs lands as uncertain or inappropriate; they open a conversation rather than end one.

A document meant to be revised#

The AUC were written to age well. Their authors expected updates as evidence matured, and later analyses have indeed flagged scenarios worth a second look. Because the reasoning behind each rating is explicit, it can be reopened and revised in the open rather than discarded. That transparency is a feature of the method, and it is a good habit for any evidence-based tool: state the logic plainly enough that a future reader can challenge it.